Key result
Outpatient phenprocoumon links to ~12 bleeds per 100 treatment-years, mostly managed with vitamin K.
Why the study?
Management strategies for bleeding complications in patients on oral anticoagulation require clarification regarding optimal antagonization approaches and outcomes.
Cohort (n=45)
No
In a small cohort of outpatients on phenprocoumon, bleeding complications were mostly minor and effectively managed with dose reduction and vitamin K.
Answers are grounded in this paper and cite their sources.
Bleeding rates with phenprocoumon warrant ongoing outpatient vigilance; leaves open need for larger prospective studies on real-world incidence.
Overdose or bleeding with oral anticoagulation requires gradual antagonization of the drugs. Minor bleedings are most commonly managed by temporarily discontinuing treatment and by giving vitamin K to antagonize the coumarin derivative effects. Major bleedings, in contrast, especially intracranial hemorrhages, require immediate antagonization of anticoagulation. This is also necessary in required major surgery of anticoagulated patients. Instant normalization of hemostasis in such cases is achieved by the administration of clotting factors, in particular prothrombin complex concentrates. The use of fresh frozen plasma, instead, is less useful. The treatment with prothrombin complex concentrates requires a strict risk-benefit estimation and laboratory monitoring is recommended to optimize dosage adjustment. A 2-year follow-up of 45 out-patients receiving phenprocoumon at our center revealed a total of 11 bleeding complications (11.6/100 treatment-years, 10 minor and 1 major bleeding). Discontinuing or reducing oral anticoagulation together with vitamin K were the methods most frequently used to efficiently manage hemorrhages, whereas prothrombin complex concentrates were only used in one case with major bleeding. Oral anticoagulation appeared to be an enhancing factor for an otherwise existing bleeding diathesis rather than a genuine cause for hemorrhages.
No takes yet. Share an insight, caveat, or question.
Pindur et al. (1999) conducted a cohort in Oral anticoagulation therapy (n=45). Phenprocoumon was evaluated on Bleeding complications. Among 45 out-patients receiving phenprocoumon over 2 years, there were 11 bleeding complications, mostly managed by discontinuing treatment and vitamin K.
Synapse has enriched 10 related papers. Consider them for comparative context: